Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,881 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.

NCT01978314
Conditions
Chronic Kidney Disease, Acute Kidney Injury
Interventions
75 mg / 6 mL VFI™
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
19 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Terminated Phase 4 Interventional Results available

Artegraft Versus Propaten Dialysis Grafts

NCT02099344
Conditions
ESRD, Renal Failure
Interventions
Artegraft, Propaten
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

NCT02360644
Conditions
Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
Aurora, Colorado • Pittsburgh, Pennsylvania
Conditions
Kidney Diseases, Cardiometabolic Risk Factors
Interventions
ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Chronic Kidney Diseases, Bladder Dysfunction, Bladder Absence, Posterior Urethral Valve, Neurogenic Bladder, Bladder Exstrophy, Bladder Outlet Obstruction, Failure, Kidney, Transplant
Interventions
Concomitant Renal and Urinary Bladder Allograft Transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota
Conditions
Uncontrolled Hypertension, Chronic Kidney Diseases
Interventions
CIN-107, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 65 more
Conditions
Pediatric Kidney Disease
Interventions
Sulforaphane
Drug
Lead sponsor
University of Rochester
Other
Eligibility
1 Year to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, New York
Conditions
Kidney Disease, Chronic, Endothelial Dysfunction
Interventions
Beet It Sport Shot, Nitrate-depleted placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Terminated Phase 2 Interventional Results available

A Study in Participants With Diabetic Kidney Disease

NCT01113801
Conditions
Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
Interventions
LY2382770, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Representational Intervention to Promote Preparation for End-of-life Decision Making

NCT01259011
Conditions
End Stage Renal Disease
Interventions
the SPIRIT intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Chronic Kidney Disease
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
119
States / cities
Huntsville, Alabama • Montgomery, Alabama • Sheffield, Alabama + 106 more
Conditions
Anemia
Interventions
darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
22
States / cities
Los Angeles, California • Mather, California • Stanford, California + 18 more
Completed Not applicable Interventional Results available

Blood Pressure in Dialysis Patients

NCT01421771
Conditions
Hypertension, Renal Failure Chronic Requiring Hemodialysis, Blood Pressure, Dialysis
Interventions
Antihypertensive Agents, Dry weight Challenge, Extend dialysis treatment time and re-challenge estimated dry weight
Drug · Other · Dietary Supplement
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
21
States / cities
Boston, Massachusetts • Concord, Massachusetts • Jamaica Plain, Massachusetts + 9 more
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizuamb, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more
Conditions
ESRD
Interventions
None. This is a qualitative interview study.
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Gatos, California • Menlo Park, California • Milpitas, California + 7 more
Conditions
End Stage Kidney Disease, End Stage Renal Disease
Interventions
Assistance to perform Peritoneal Dialysis (PD) at home
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Emeryville, California • Fremont, California • Milpitas, California + 3 more
Completed Not applicable Interventional

Decision Aid for Renal Therapy

NCT03522740
Conditions
Chronic Kidney Diseases, Kidney Failure, Chronic
Interventions
Decision Aid for Renal Therapy
Other
Lead sponsor
Tufts University
Other
Eligibility
70 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
San Diego, California • Chicago, Illinois • Portland, Maine + 1 more
Conditions
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions
Best Practice, Tocilizumab
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
Interventions
Physiologic Insulin Resensitization (PIR)
Other
Lead sponsor
Well Cell Global
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Completed Not applicable Interventional

Early Identification and Action in CKD

NCT02208674
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Protocolized, pharmacist-delivered CKD Action Plan
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Danville, Pennsylvania
Conditions
Chronic Kidney Disease
Interventions
advance care planning
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Springfield, Massachusetts
Completed Phase 2 Interventional Results available

Bone Mass and Strength After Kidney Transplantation

NCT02224144
Conditions
End Stage Renal Disease, Kidney Transplantation, Bone Loss, Fractures, Vascular Calcifications
Interventions
Vitamin D3, Calcitriol, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York